ACADIA Pharmaceuticals In...

16.31
-0.30 (-1.81%)
At close: Apr 01, 2025, 3:59 PM
16.65
2.10%
Pre-market: Apr 02, 2025, 04:37 AM EDT

Company Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.

The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's.

ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. logo
Country United States
IPO Date May 27, 2004
Industry Biotechnology
Sector Healthcare
Employees 653
CEO Catherine E. Owen Adams

Contact Details

Address:
12830 El Camino Real
San Diego, California
United States
Website https://www.acadia-pharm.com

Stock Details

Ticker Symbol ACAD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001070494
CUSIP Number 004225108
ISIN Number US0042251084
Employer ID 06-1376651
SIC Code 2834

Key Executives

Name Position
Catherine E. Owen Adams Chief Executive Officer & Director
Jennifer J. Rhodes J.D. Chief Legal Officer & Secretary
Mark C. Schneyer Executive Vice President & Chief Financial Officer
Rob Ackles Chief People Officer
Dr. Elizabeth H.Z. Thompson Ph.D. Head of Research & Development
Dr. Kevin R. Oliver Ph.D. Chief Business Officer
James K. Kihara Senior Vice President of Finance
Stephen R. Davis J.D. Consultant
Thomas Andrew Garner Chief Commercial Officer

Latest SEC Filings

Date Type Title
Mar 26, 2025 4 Filing
Mar 26, 2025 4 Filing
Mar 26, 2025 4 Filing
Mar 26, 2025 4 Filing
Mar 26, 2025 4 Filing
Mar 06, 2025 4 Filing
Feb 27, 2025 10-K Annual Report
Feb 26, 2025 8-K Current Report
Feb 25, 2025 4 Filing
Feb 25, 2025 4 Filing